Sequential Bendamustine and Rituximab Plus Cytarabine and Rituximab Regimen With or Without Acalabrutinib Shows Promise for Patients With MCL
Results from the FitMCL 1.0 and 2.0 Pilot Studies
Results from the FitMCL 1.0 and 2.0 Pilot Studies
According to pooled data from 2 pilot studies published in Clinical Lymphoma, Myeloma & Leukemia, administering bendamustine and rituximab (BR) plus cytarabine and rituximab (CR) sequentially, rather than alternating, with or without acalabrutinib, yielded promising results among patients with mantle cell lymphoma (MCL), demonstrating potential benefits regarding toxicities and subsequent dose modifications.
Dilan A Patel, Washington University in St Louis School of Medicine, St Louis, Missouri, and coauthors described MCL as “generally viewed as incurable.” Fit patients who are administered high-dose cytarabine-based induction regimens followed by autologous hematopoietic cell transplant and 3 years of rituximab maintenance typically respond to this standard of care treatment, but “eventually relapse, indicating a need to improve the safety and tolerability of remission induction strategies,” they stated.
Based on the strong efficacy of bendamustine-rituximab among older MCL patients, study authors designed a novel induction regimen, modeled after the Nordic Regimen for treating patients with MCL. This novel regimen substituted bendamustine-rituximab in place of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). In a second pilot study, BTK inhibitor acalabrutinib, was incorporated into the regimen. The primary endpoint of both pilot studies, FitMCL 1.0 and 2.0, was the stem cell mobilization success rate.
All patients in both FitMCL 1.0 and 2.0 successfully underwent stem cell harvest . The safety and efficacy data from both pilot studies were comparable, highlighting the potential of this approach.
Dr Patel and coauthors concluded, “The experience from our single institution pilot study suggested that sequential rather than alternating bendamustine-rituximab and cytarabine-rituximab was easier to administer from the standpoint of toxicities and subsequent dose modifications.”
“The pilot studies provided preliminary safety data supporting the development of the NCTN trial EA4181, assessing 3 different induction regimens with or without acalabrutinib,” they added.
Source:
Patel DA, Wan F, Trinkaus K, et al. Bendamustine/rituximab plus cytarabine/rituximab, with or without acalabrutinib, for initial treatment of transplant-eligible mantle cell lymphoma patients: pooled data from two pilot studies. Clin Lymphoma Myeloma Leuk. 2023; 7-23. doi:10.1016/j.clml.2023.04.003


